Theravance Biopharma (NASDAQ:TBPH) : Traders are bullish on Theravance Biopharma (NASDAQ:TBPH) as it has outperformed the S&P 500 by a wide margin of 1.8% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.8%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 2.09% in the last 1 week, and is up 3.44% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have rallied 96.32% from its 1 Year high price. On Apr 22, 2016, the shares registered one year high at $24.76 and the one year low was seen on Oct 2, 2015. The 50-Day Moving Average price is $22.69 and the 200 Day Moving Average price is recorded at $19.06.
The stock has recorded a 20-day Moving Average of 3.28% and the 50-Day Moving Average is 9.13%.
Theravance Biopharma (NASDAQ:TBPH): stock turned positive on Friday. Though the stock opened at $23.17, the bulls momentum made the stock top out at $23.63 level for the day. The stock recorded a low of $22.8 and closed the trading day at $23.46, in the green by 2.00%. The total traded volume for the day was 716,660. The stock had closed at $23 in the previous days trading.
In an insider trading activity, The Securities and Exchange Commission has divulged in a Form 4 filing that the officer (Sr. VP, Technical Operations) of Theravance Biopharma, Inc., Lee Junning had purchased shares worth of $116,100 in a transaction dated on August 18, 2015. A total of 9,000 shares were purchased at a price of $12.9 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
Theravance Biopharma, Inc. (Theravance Biopharma) is a biopharmaceutical company. The Company is engaged to create value from a diverse set of assets: an approved product; a development pipeline of mid- and late-stage assets, and a productive research platform designed for long-term growth. VIBATIV (telavancin), its commercial product, is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. TD-4208 is an investigational long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily, nebulized treatment for chronic obstructive pulmonary disease (COPD). Axelopran (TD-1211) is an investigational potential once-daily, oral treatment for opioid-induced constipation (OIC). Its earlier-stage clinical assets represent approaches for potentially treating diseases of the lung and gastrointestinal tract and infectious disease.